The tubeless future of insulin pumps just got a little more real.
Tandem Diabetes has been quietly showing off its upcoming tubeless version of its Tandem Mobi pump — a new form factor that brings Tandem into the growing patch pump arena currently dominated by Omnipod. And if you thought this was still years away, think again. The company is targeting an early 2026 launch, and it could be a game changer.
This updated wear option of Tandem Mobi features an adhesive-patch infusion set that lets users slide their Mobi pump into. This update introduces a new cartridge that allows current and future Mobi users to wear their pump in this way. This gives users yet another option for wearing their pump.
What sets this patch pump apart is what’s under the hood — a new 7-day SteadiSet infusion set, which was just cleared by the FDA and will power the tubeless system. This could makes Tandem Mobi the first-ever patch pump with a full 7-day wear time — more than double what Omnipod 5 currently offers. It’s a leap forward that could reshape the market. As we’ve seen with CGMs, longer wear is where we’re headed.
Daily insulin needs will dictate just how long the 200 unit cartridge will last. We expect users can leave the patch on for the full seven days, and swap out their cartridge when it drys out. Either way, this is a huge improvement overall.
The patch itself will likely be applied with an applicator similar to a CGM. Once it’s on, users can slide the pump on and off using a new side-clip design. It's versatile and cleaner looking than the current tubed Mobi, and could be the bridge for users curious about tubeless but not wanting to leave the Tandem ecosystem.
Of course, we’ve been following the rest of the market closely — Beta Bionics, Medtronic, and Omnipod are all working on their next iterations.
To hear more about the Tubeless Mobi, check out out the video at the top of the page for a full breakdown, including visuals, key details, and how it fits into the future of diabetes tech. We’ll keep you updated as this story develops.
Want more?
For the latest diabetes tech, join our free newsletter.
If you’re enjoying our content, consider joining Diabetech All Access—our premium membership with exclusive stories, Live Q&As, and industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving.
Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.